Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: K22CA266737, P01 CA244118, R35 CA197633
NCI NIH HHS
Grant: P01 CA244118
NCI NIH HHS
Grant: K22 CA266737
NCI NIH HHS
Grant: R35 CA197633
National Institutes of Health
Grant: 1P01CA244118-01A1
Combination Therapies to Defeat Melanoma Resistance
National Institutes of Health
Grant: 5K22CA266737-03
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
National Institutes of Health
Grant: 2R35CA197633-08
Next Generation Cancer Immunotherapies to Defeat Melanoma
FWCI
0.00
Citation Percentile
0.3%
Fields of Study
MeSH Terms
Keywords